Status:
UNKNOWN
A Study: Pure CBD as Single-agent for Solid Tumor.
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Increasing lines of evidence support an antitumourigenic effect of cannabinoids, including the cannabidiol (CBD) which does not posses the psychotropic effects of D9-tetrahydrocannabinol (THC). These ...
Eligibility Criteria
Inclusion
- Confirmed solid cancer
- Approved license for using cannabis (from the ministry of health: Israel)
- Progression of all the available standard therapy / unfit to standard therapy according to oncologist's view
- Measurable disease as determined by RECIST
- Life expectancy of at least 6 months
- Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2
- Aged 18 years old and more
Exclusion
- Received cannabis therapy for any indication
- Previous systemic therapy of less than 3 weeks prior to and, if present, any acute toxicity \> grade 1.
- Clinically significant cardiac disease or any history of psychosis
- Pregnancy or breast feeding
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02255292
Start Date
November 1 2014
End Date
July 1 2015
Last Update
October 2 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.